brain interface News
-
Newly Published Studies Show Motor Recovery in Chronic Stroke Patients
Neurolutions CSO and Founder Dr. Eric Leuthardt has contributed to two recently published studies showing proof that brain-computer interface therapy with the IpsiHand benefits the brain's motor networks and also motor recovery in chronic stroke patients with extended usage. Brain-Computer Interface – The Future of Rehabilitation Brain-computer interface rehabilitation using the IpsiHand ...
By Neurolutions
-
Researchers Have Developed a Brain-Computer Interface That Adds a Soundtrack to Your Life
“The public currently perceives music predominantly as a medium for entertainment, but music has a much bigger footprint in human history than this. Historically, it’s served many important roles in society, from social cohesion to mother-infant bonding to healing,” say researchers who have developed a music-based brain-computer interface (BCI) that helps people struggling with ...
By ni2o, Inc.
-
Synchron announces first direct-thought tweet, “Hello World,”using an implantable brain computer interface
Synchron, a brain computer interface company, today announced a Twitter takeover by Philip O’Keefe, one of the patients implanted with the Stentrode brain computer interface. Mr. O’Keefe is the first person to successfully message the world on social media directly through thought using an implantable brain computer interface. Mr. O’Keefe, a 62-year-old man with amyotrophic ...
-
The Surgeon Who Sees a Future in Brain-Computer Interfaces
Sounds like something out of a sci-fi movie, right? Dr. Eric Leuthardt has spent a lot of time imagining the future and in all the possible future scenarios depicted in science fiction, "where were the neural prosthetics?", he asks. In addition to his duties as a neurosurgeon at Washington University in St. Louis, Leuthardt has published two novels and written an award-winning play ...
By Neurolutions
-
Synchron Expands Advisory Board as Brain-Computer Interface Device Stentrode Advances into Patients in US Clinical Trials
Synchron, a brain computer interface (BCI) company, today announced the expansion of its advisory board comprised of industry pioneers, to provide strategic guidance in support of the Company’s clinical development plans, corporate strategy and growth. The members of the advisory board are visionaries across the technology, neuroscience and medical device industry, which include Edward ...
-
ClearPoint Neuro Congratulates Blackrock Neurotech on Receiving Breakthrough Device Designation from the FDA for the MoveAgain Brain-Computer Interface System
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner Blackrock Neurotech for receiving Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its groundbreaking MoveAgain Brain Computer Interface (BCI) system. There are an estimated ...
-
Neurolutions Receives U.S. Food and Drug Administration De Novo Market Authorization for IpsiHand
IpsiHand robotic hand-piece uniquely leverages brain-computer interface technology for chronic stroke rehabilitation IpsiHand also has been granted U.S. FDA Breakthrough Device Designation Neurolutions, Inc., a medical device company developing and commercializing a first-of-its-kind device leveraging brain-computer interface (BCI) technology for upper extremity chronic stroke rehabilitation, ...
By Neurolutions
-
EMOTIV Enlists Two Machine Learning Heavyweights as AI Takes Aim at the Human Brain
EMOTIV, the bioinformatics pioneer advancing understanding of the human brain using electroencephalography (EEG), today added two renowned scientists to its executive leadership team, naming Dr. Gary William Flake as Chief Technology Officer (CTO) and Dr. Scott Rickard as Chief AI Scientist. The new hires underscore EMOTIV’s strategic objectives to meet the quickening pace of advancements ...
By Emotiv Inc.
-
atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders
atai Life Sciences ("atai" or the "Company"), a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has acquired a majority stake in Delaware based Psyber, a company dedicated to developing interventions to improve various mental health disorders and induce behavioural changes through brain computer interface (BCI)-enabled ...
-
Synchron Announces Enrollment of First Patient in U.S. Endovascular Brain Computer Interface Study COMMAND in Patients With Severe Paralysis
Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S. Paralysis is a devastating condition for more than 5 million patients in the United States Synchron, an endovascular brain-computer (BCI) interface company, today announced the enrollment of the first patient in the US clinical trial, COMMAND, for patients ...
-
Team Gleason Partners with Synchron to Redefine Accessibility
Team Gleason and Synchron, an endovascular brain computer interface company, today announced a partnership agreement to provide patient-focused feedback on their platform to transform daily life for patients with physical and speech disabilities like ALS, muscular dystrophy, and cerebral palsy. The partnership will enable Synchron to collaborate with Team Gleason’s expert committees and an ...
-
Synchron Announces Long-Term Safety Results from Fully Implanted Endovascular Brain-Computer Interface Stentrode for Severe Paralysis
Four Patients With ALS Who Received Stentrode™ Implant Gained Ability to Perform Daily Online Tasks No Serious Adverse Events Reported after 12 Months Synchron, a brain computer interface (BCI) company, today announced the results from a study in which four people with ALS received an implant of Synchron’s Stentrode™ device, a small mesh-like material inserted ...
-
Synchron Appoints Kurt Haggstrom as Chief Commercial Officer
Synchron, an endovascular brain-computer (BCI) interface company, today announced the appointment of Kurt Haggstrom as Chief Commercial Officer. Haggstrom brings an extensive background in medical device commercialization and product launches, with a technical background in R&D engineering, holding over 20 U.S. patents. “I am honored and excited to join the Synchron team and be part of ...
-
Synchron Announces First Human U.S. Brain-Computer Interface Implant
Synchron, an endovascular brain-computer interface (BCI) company, today announced the first human BCI implant in the United States. This procedure represents a significant technological milestone for scalable BCI devices and is the first to occur in the U.S. using an endovascular BCI approach, which does not require invasive open-brain surgery. The procedure was performed at Mount Sinai West in ...
-
Internationally Renowned Neurosurgeon and Accomplished Researcher Dr. Linda M. Liau Joins ClearPoint Neuro Board of Directors
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Linda M. Liau, MD, PhD, MBA, has been appointed to the Company’s Board of Directors effective immediately. Dr. Linda M. Liau is Professor and W. Eugene Stern Chair of the Department of Neurosurgery at the ...
-
Synchron receives green light from FDA to begin breakthrough trial of implantable brain computer interface in US
Synchron, a venture-backed brain data transfer company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for its flagship product, the Stentrode™ motor neuroprosthesis. This early feasibility study (EFS) of the device will begin later this year at Mount Sinai Hospital, New York, and will assess the safety ...
-
Breakthrough Israeli stroke therapy technology BrainQ announces a $40M funding round
Funding round led by Hanaco Ventures, joined by Dexcel Pharma and Peregrine Ventures, and existing investors. BrainQ’s investigational neurorecovery technology has been granted FDA Breakthrough Device Designation, and is set to be trialed in a multicenter pivotal study for stroke patients in select hospitals across the US. Jerusalem, Israel – August 16, 2021 – Israeli ...
-
Neurolutions IpsiHand Stroke Rehabilitation Device Authorized by FDA
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use in patients 18 and older undergoing stroke rehabilitation to facilitate muscle re-education and for maintaining or increasing range of motion. The Neurolutions IpsiHand Upper Extremity Rehabilitation System (IpsiHand System) is a Brain-Computer-Interface (BCI) device that assists in rehabilitation ...
By Neurolutions
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you